BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

654 related articles for article (PubMed ID: 30340643)

  • 1. Stereotactic ablative radiotherapy (SABR) as primary, adjuvant, consolidation and re-treatment option in pancreatic cancer: scope for dose escalation and lessons for toxicity.
    Goldsmith C; Plowman PN; Green MM; Dale RG; Price PM
    Radiat Oncol; 2018 Oct; 13(1):204. PubMed ID: 30340643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stereotactic ablative radiotherapy for ultra-central lung tumors: prioritize target coverage or organs at risk?
    Murrell DH; Laba JM; Erickson A; Millman B; Palma DA; Louie AV
    Radiat Oncol; 2018 Apr; 13(1):57. PubMed ID: 29606150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stereotactic body radiotherapy (SBRT) in recurrent or oligometastatic pancreatic cancer : A toxicity review of simultaneous integrated protection (SIP) versus conventional SBRT.
    Gkika E; Adebahr S; Kirste S; Schimek-Jasch T; Wiehle R; Claus R; Wittel U; Nestle U; Baltas D; Grosu AL; Brunner TB
    Strahlenther Onkol; 2017 Jun; 193(6):433-443. PubMed ID: 28138949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypofractionated image-guided breath-hold SABR (stereotactic ablative body radiotherapy) of liver metastases--clinical results.
    Boda-Heggemann J; Dinter D; Weiss C; Frauenfeld A; Siebenlist K; Attenberger U; Ottstadt M; Schneider F; Hofheinz RD; Wenz F; Lohr F
    Radiat Oncol; 2012 Jun; 7():92. PubMed ID: 22710033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and dosimetric predictors of radiation pneumonitis in early-stage lung cancer treated with Stereotactic Ablative radiotherapy (SABR) - An analysis of UK's largest cohort of lung SABR patients.
    Saha A; Beasley M; Hatton N; Dickinson P; Franks K; Clarke K; Jain P; Teo M; Murray P; Lilley J
    Radiother Oncol; 2021 Mar; 156():153-159. PubMed ID: 33333139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes of single fraction stereotactic ablative radiotherapy for lung metastases.
    Filippi AR; Badellino S; Guarneri A; Levis M; Botticella A; Mantovani C; Ragona R; Racca P; Buffoni L; Novello S; Ricardi U
    Technol Cancer Res Treat; 2014 Feb; 13(1):37-45. PubMed ID: 23819496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of Monte Carlo algorithm for compliance with RTOG 0915 dosimetric criteria in peripheral lung cancer patients treated with stereotactic body radiotherapy.
    Pokhrel D; Sood S; Badkul R; Jiang H; McClinton C; Lominska C; Kumar P; Wang F
    J Appl Clin Med Phys; 2016 May; 17(3):277-293. PubMed ID: 27167284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dosimetric comparison of brachyablation and stereotactic ablative body radiotherapy in the treatment of liver metastasis.
    Pennington JD; Park SJ; Abgaryan N; Banerjee R; Lee PP; Loh C; Lee E; Demanes DJ; Kamrava M
    Brachytherapy; 2015; 14(4):537-42. PubMed ID: 25944395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Should organs at risk (OARs) be prioritized over target volume coverage in stereotactic ablative radiotherapy (SABR) for oligometastases? a secondary analysis of the population-based phase II SABR-5 trial.
    Eufemon Cereno R; Mou B; Baker S; Chng N; Arbour G; Bergman A; Liu M; Schellenberg D; Matthews Q; Huang V; Mestrovic A; Hyde D; Alexander A; Carolan H; Hsu F; Miller S; Atrchian S; Chan E; Ho C; Mohamed I; Lin A; Berrang T; Bang A; Jiang W; Lund C; Pai H; Valev B; Lefresne S; Tyldesley S; Olson RA
    Radiother Oncol; 2023 May; 182():109576. PubMed ID: 36822355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Late Toxicity and Long-Term Local Control in Patients With Ultra-Central Lung Tumours Treated by Intensity-Modulated Radiotherapy-Based Stereotactic Ablative Body Radiotherapy With Homogenous Dose Prescription.
    Mihai AM; Armstrong PJ; Hickey D; Milano MT; Dunne M; Healy K; Thirion P; Heron DE; ElBeltagi N; Armstrong JG
    Clin Oncol (R Coll Radiol); 2021 Oct; 33(10):627-637. PubMed ID: 34092462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Efficacy of Stereotactic Ablative Radiation Therapy for Renal Cell Carcinoma Extracranial Metastases.
    Wang CJ; Christie A; Lin MH; Jung M; Weix D; Huelsmann L; Kuhn K; Meyer J; Desai N; Kim DWN; Pedrosa I; Margulis V; Cadeddu J; Sagalowsky A; Gahan J; Laine A; Xie XJ; Choy H; Brugarolas J; Timmerman R; Hannan R
    Int J Radiat Oncol Biol Phys; 2017 May; 98(1):91-100. PubMed ID: 28587057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive factors for local control in primary and metastatic lung tumours after four to five fraction stereotactic ablative body radiotherapy: a single institution's comprehensive experience.
    Thibault I; Poon I; Yeung L; Erler D; Kim A; Keller B; Lochray F; Jain S; Soliman H; Cheung P
    Clin Oncol (R Coll Radiol); 2014 Nov; 26(11):713-9. PubMed ID: 25085765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stereotactic ablative radiotherapy for reirradiation of locally recurrent lung tumors.
    Trakul N; Harris JP; Le QT; Hara WY; Maxim PG; Loo BW; Diehn M
    J Thorac Oncol; 2012 Sep; 7(9):1462-5. PubMed ID: 22895143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stereotactic Ablative Radiation Therapy for Large (≥5 cm) Non-small Cell Lung Carcinoma.
    McDermott RL; Mihai A; Dunne M; Keys M; O'Sullivan S; Thirion P; ElBeltagi N; Armstrong JG
    Clin Oncol (R Coll Radiol); 2021 May; 33(5):292-299. PubMed ID: 33309479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stereotactic ablative body radiation therapy for primary kidney cancer: a 3-dimensional conformal technique associated with low rates of early toxicity.
    Pham D; Thompson A; Kron T; Foroudi F; Kolsky MS; Devereux T; Lim A; Siva S
    Int J Radiat Oncol Biol Phys; 2014 Dec; 90(5):1061-8. PubMed ID: 25442039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stereotactic ablative radiotherapy (SABR) using 70 Gy in 10 fractions for non-small cell lung cancer: exploration of clinical indications.
    Li Q; Swanick CW; Allen PK; Gomez DR; Welsh JW; Liao Z; Balter PA; Chang JY
    Radiother Oncol; 2014 Aug; 112(2):256-61. PubMed ID: 25108807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk Adapted Ablative Radiotherapy After Intensive Chemotherapy for Locally Advanced Pancreatic Cancer.
    Rossi G; Simoni N; Paiella S; Rossi R; Venezia M; Micera R; Malleo G; Salvia R; Giuliani T; Di Gioia A; Auriemma A; Milella M; Guariglia S; Cavedon C; Bassi C; Mazzarotto R
    Front Oncol; 2021; 11():662205. PubMed ID: 33959509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stereotactic ablative body radiotherapy for lung cancer.
    Franks KN; Jain P; Snee MP
    Clin Oncol (R Coll Radiol); 2015 May; 27(5):280-9. PubMed ID: 25746732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stereotactic body radiotherapy using CyberKnife for locally advanced unresectable and metastatic pancreatic cancer.
    Su TS; Liang P; Lu HZ; Liang JN; Liu JM; Zhou Y; Gao YC; Tang MY
    World J Gastroenterol; 2015 Jul; 21(26):8156-62. PubMed ID: 26185389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can dosimetry affect local control and survival in patients with early-stage lung cancer treated with Stereotactic Ablative Radiotherapy (SABR)? An analysis of the UK's largest cohort of lung SABR patients.
    Saha A; Beasley M; Hatton N; Dickinson P; Franks K; Clarke K; Jain P; Teo M; Murray P; Lilley J
    Acta Oncol; 2021 Apr; 60(4):505-512. PubMed ID: 33491521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.